Can-Fite Fact Sheet

CAN-FITE BioPharma Ltd

SELECT FINANCIALS

Ticker: NYSE - CANF

Stock Price: $2.32
Shares Outstanding: 6 M ADRs
Market Cap: $14 M

Therapeutic Target
A3 adenosine receptor

Pipeline Drugs
Small molecules, Orally bioavailable

Bind with high selectivity to the A3 adenosine receptor (A3AR)
Over-expressed in inflammatory and cancer cells

Proven Therapeutic Effect
Efficacious in Phase II and Phase III studies

Excellent Safety Profile
Demonstrated in >1,600 patients

Analyst Coverage

HCW
H.C.WAINWRIGHT&CO.
Price Target $34

DJ DAWSONJAMES SECURITIES

Raising to Buy from Neutral –
Price Target $6

AGP
AllianceGlobalPartners
Anticipating a solid 2H23-2024 as Piclidenoson & Namodenoson advance in late stage trials
Price Target $12

www.canfite.com

info@canfite.com

Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has 2 drug candidates in advanced stages of development, Piclidenoson for the treatment of psoriasis and Namodenoson for the treatment of advanced liver cancer. For each of the drugs, a registration plan has been agreed with both the U.S. FDA and the European Medicines Agency (EMA) and enrollment of patients for a pivotal Phase III clinical study is ongoing for liver cancer and underway for psoriasis. Namodenoson also has a robust anti-cancer effect against pancreatic cancer and an exploratory Phase II clinical study will be initiated in Q1 2024. Due to the liver-protective effect of Namodenoson, a Phase IIb study for the treatment SLD (NASH), is currently enrolling patients. Piclidenoson and Namodenoson have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.

Piclidenoson

Pivotal Phase III Psoriasis Study

A registration plan with a pivotal Phase III study design was agreed upon with the FDA and EMA. The prior Phase III Comfort™ trial enrolled >400 patients with moderate-to-severe psoriasis. Patients treated with Piclidenoson had a statistically significant progressive improvement along the study period compared to placebo. Piclidenoson's excellent safety profile was comparable to that of placebo and better than Otezla, a leading oral psoriasis drug on the market.

Namodenoson

Pivotal Phase III in Advanced Liver Cancer – Enrollment Ongoing

A registration plan with a pivotal Phase III study design was agreed upon with the FDA and EMA. Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of advanced liver cancer. Namodenoson is being evaluated as a 2nd or 3rd line treatment with the primary endpoint of improved overall survival. An interim analysis will be conducted after 50% of the planned 450 patients are enrolled and treated.

Exploratory Phase II in Pancreatic Cancer

An exploratory open-label Phase IIa study to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy is underway.

SLD (NASH) Phase IIb – Enrollment Ongoing

Namodenoson is in a Phase IIb SLD (NASH) multicenter, randomized, double-blind, placebo-controlled study with biopsy-confirmed SLD and F1-3 fibrosis. The former Phase IIa study met all efficacy and safety endpoints.

Corporate Partnerships – Current Out-Licensing Deals

ewo pharma	Eastern Europe*	Psoriasis, Liver Cancer, SLD
Gebro Pharma	Spain, Switzerland, Austria	Psoriasis
CMS 康哲药业	China, Taiwan, Hong Kong, Macao	Psoriasis, Liver Cancer, SLD
Chong Kun Dang Pharm.	South Korea	Liver Cancer, SLD
KYONGBO	South Korea	Psoriasis
cipher	Canada	Psoriasis
VETBIOLIX	Global	Piclidenoson - Pets' Osteoarthritis

*Estonia, Lithuania, Latvia, Bosnia, Bulgaria, Croatia, Czech Republic, Hungary, Moldavia, North Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia

$20M received in upfront and milestone payments

$130M potential based on regulatory and sales milestones

Typical Deal Structure

- Up-front money upon signing a distribution deal
- Regulatory milestone payments
- Royalties (double-digits)
- Sales milestone payments